The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...

The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

US FDA has approved its first ever non-opioid painkiller called suzetrigine. Experts believe it will prevent addiction problems unlike existing opioids.

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...